Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreLondon South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some decent news on advfn, apparently Axumin rolled out to France commercially this week, some news about phase 3 glioma trial/data being submitted to the FDA also
Todays RNS is colossal re treatment for haemophilia.
Net assets up 32.5% in the last 6 months and fully funded going forward, what's not to like, though will probably lead to a share price fall in this market.
Some good abstracts released this week.
Haemophilia B results - I don't claim to fully understand this condition, but 2/2 patients fully cured with no side-effects sounds positive.
They are exposing the co to more risk and with a 50% premium, sellers (including me) are saying goodbye. I have kept a decent chunk because this is a well run outfit run by top brains who know their field. Just a question of risk and I'm playing it a bit safe.
Full page article in today’s Times.
You may well be right, sotolo, because hardly anyone chooses (and you have to) to get their divis in cash. They are normally paid in shares, which is possibly why this site seems to say they are covered. Not sure either now about the PE but they seem to be able to pick hightec winners. It is volatile now and if the next piece of news is positive, would be sensible to cream off, I suppose.
That would mean they are paying divis largely from capital. I don't think so! Anyway, market reaction to the profit-takers is very positive, so I hope I am right and your publications have this incorrect. I could use one share gong right at this time.
Yes would be very cheap with pe of 10 but I read the pe as being 344 (on Thisismoney, Barclays etc ) and earning per shar of just ¾ of a penny?
Hope a few followed my advice.
As usual my limit buy was too low so I judged the market today and got in hopefully at the turn. MMs now seem to have their hands full with buys at this level! Hopefully my persistence might pay off on this one. Losing on a lot of others right now but thats the stock market. P.S. If you put in limit bids and then overrule them, PLEASE remember to go back immediately to your limit screen and wipe it clean, or you could end up with double portion.
Shouldn't be telling you this (because my limit buy is still a trifle lower). Hoping the lemming fever will hang on until at least tomorrow's kick off!
So much hot money pulling out that these are now looking dramatically oversold so I have placed a limit but a tad lower to grab a few more at silly price with what remains of cash in this account. The getrichquick brigade will kick themselves in two years when SYNC tops £5 Do the research yourself though. I'm no expert but see last of my posts.
Earnings per Share 26.21 and PE 10.40.
Can make out a robust case for this still being CHEAP!!!
Decided to hang on. Obviously lots of short termers booking a fast buck
Ohhhh baby baby
£3 smashed. £2bn MCAP. A shining star of a future biotech powerhouse perhaps?
I have to ask myself ''How long before the stumble?' Of course the vertical ascent may continue for a long time, but I think sometime soon it will be the time to take a few chips off the table. Must check when my gain is 100%
Some very good presentations out from Nightstar and Autolus recently, worth a read.
Smashing company. An honour to have a small stake in.
Wish more of mine looked like this.
I did think Valirx's VAL201 would be a potential superb complementary product for Axumin. Imagine controlling the PET imaging of prostate as well as a therapeutic anti-cancer agent with no side effects? (TBC in further trials anyway). Especially since Axumin may also work well in Breast cancer.
from Blue Earth today. One thing SYNC is falling behind on is adding to its newco portfolio. As far as I recall not added since the first flush when the theory was to add at least one a year. I would have thought with Welcome as a partner SYNC must have queue of exciting prospects. Lets be adding one then! Suspect the reason may be that it might mean dropping an existing duffer and they are reluctant to do that.
Hello there, yes I'm still around and keep my holdings in SYNC. It seems the SP has plateaued slightly of late, however Blue Earth and Nightstar seem to be plodding forward at a rate of knots, so I suspect this is partly because the progress was already priced into the SP. Very happy with Valirx's technical progress and patent news as well, highly enjoy the technical potential as well, SCLP seem to be doing OK too so there's a reasonable amount of funky UK Biotech going on right now (I am not fully researched nor invested in SCLP, but from a laymans overview it appears like a nice technology). Nightstar (part of the SYNC portfolio) is actively out there curing (or preventing blindness) in a bunch of clinical trials, I am not sure whether there is any competition in the states, but the progress seems good from what has been publicly reported. It's now treating Choroideremia and X-linked retinitis pigmentosa, with Best Vitelliform macular dystrophy and Stargardt disease in the pipeline. The general concept of using an engineering virus to correct DNA mutations and provide functional copies of key proteins is good. But it does require surgery (i.e. it's not in pill form) so I would imagine the training curve will be steep for the rollout.
It feels like time for SYNC to be adding to the seven cos in their youngbloods group. Four are now comparatively mature and the money could come from small sales of ones which have been floated. I am sure they already have their eye on a few. RNS not expected for a few months yet but this is the type on investment which can always surprise and delight.
Is Noise still out there? This still has much further to go. I wish I had invested more